Literature DB >> 23148227

Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation.

Dan Wu1, Toshinori Ozaki, Yukari Yoshihara, Natsumi Kubo, Akira Nakagawara.   

Abstract

Representative tumor suppressor p53 plays a critical role in the regulation of proper DNA damage response. In this study, we have found for the first time that Runt-related transcription factor 1 (RUNX1) contributes to p53-dependent DNA damage response. Upon adriamycin (ADR) exposure, p53 as well as RUNX1 were strongly induced in p53-proficient HCT116 and U2OS cells, which were closely associated with significant transactivation of p53 target genes, such as p21(WAF)(1), BAX, NOXA, and PUMA. RUNX1 was exclusively expressed in the cell nucleus and formed a complex with p53 in response to ADR. Chromatin immunoprecipitation assay demonstrated that p53 together with RUNX1 are efficiently recruited onto p53 target gene promoters following ADR exposure, indicating that RUNX1 is involved in p53-mediated transcriptional regulation. Indeed, forced expression of RUNX1 stimulated the transcriptional activity of p53 in response to ADR. Consistent with these observations, knockdown of RUNX1 attenuated ADR-mediated induction of p53 target genes and suppressed ADR-dependent apoptosis. Furthermore, RUNX1 was associated with p300 histone acetyltransferase, and ADR-dependent acetylation of p53 at Lys-373/382 was markedly inhibited in RUNX1 knockdown cells. In addition, knockdown of RUNX1 resulted in a significant decrease in the amount of p53-p300 complex following ADR exposure. Taken together, our present results strongly suggest that RUNX1 is required for the stimulation of p53 in response to DNA damage and also provide novel insight into understanding the molecular mechanisms behind p53-dependent DNA damage response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23148227      PMCID: PMC3543018          DOI: 10.1074/jbc.M112.402594

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

Review 1.  p53 function and dysfunction.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1992-08-21       Impact factor: 41.582

2.  Definition of a consensus binding site for p53.

Authors:  W S el-Deiry; S E Kern; J A Pietenpol; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

3.  t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.

Authors:  H Miyoshi; K Shimizu; T Kozu; N Maseki; Y Kaneko; M Ohki
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

4.  Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis.

Authors:  Q Wang; T Stacy; M Binder; M Marin-Padilla; A H Sharpe; N A Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 5.  p53: at the crossroads of molecular carcinogenesis and risk assessment.

Authors:  C C Harris
Journal:  Science       Date:  1993-12-24       Impact factor: 47.728

6.  Sequence-specific transcriptional activation is essential for growth suppression by p53.

Authors:  J A Pietenpol; T Tokino; S Thiagalingam; W S el-Deiry; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

7.  RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53.

Authors:  Sandy F Wotton; Karen Blyth; Anna Kilbey; Alma Jenkins; Anne Terry; Florence Bernardin-Fried; Alan D Friedman; Euan W Baxter; James C Neil; Ewan R Cameron
Journal:  Oncogene       Date:  2004-07-15       Impact factor: 9.867

8.  Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia.

Authors:  T R Golub; G F Barker; S K Bohlander; S W Hiebert; D C Ward; P Bray-Ward; E Morgan; S C Raimondi; J D Rowley; D G Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

9.  Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2.

Authors:  A Takahashi; M Satake; Y Yamaguchi-Iwai; S C Bae; J Lu; M Maruyama; Y W Zhang; H Oka; N Arai; K Arai
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

10.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

View more
  26 in total

1.  Network of microRNA, transcription factors, target genes and host genes in human mesothelioma.

Authors:  Guanhua Zhang; Zhiwen Xu; Ning Wang
Journal:  Exp Ther Med       Date:  2017-04-04       Impact factor: 2.447

2.  Identification of tRNA-derived small RNA (tsRNA) responsive to the tumor suppressor, RUNX1, in breast cancer.

Authors:  Nicholas H Farina; Stephanie Scalia; Caroline E Adams; Deli Hong; Andrew J Fritz; Terri L Messier; Veronica Balatti; Dario Veneziano; Jane B Lian; Carlo M Croce; Gary S Stein; Janet L Stein
Journal:  J Cell Physiol       Date:  2020-01-10       Impact factor: 6.384

Review 3.  The RUNX family: developmental regulators in cancer.

Authors:  Yoshiaki Ito; Suk-Chul Bae; Linda Shyue Huey Chuang
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

Review 4.  Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Authors:  Yoshihiro Hayashi; Yuka Harada; Hironori Harada
Journal:  Leukemia       Date:  2022-03-30       Impact factor: 11.528

Review 5.  A Systematic Review of the Role of Runt-Related Transcription Factor 1 (RUNX1) in the Pathogenesis of Hematological Malignancies in Patients With Inherited Bone Marrow Failure Syndromes.

Authors:  Janan Illango; Archana Sreekantan Nair; Rajvi Gor; Ransirini Wijeratne Fernando; Mushrin Malik; Nabeel A Siddiqui; Pousette Hamid
Journal:  Cureus       Date:  2022-05-26

6.  Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia.

Authors:  Iléana Antony-Debré; Vladimir T Manchev; Nathalie Balayn; Dominique Bluteau; Cécile Tomowiak; Céline Legrand; Thierry Langlois; Olivia Bawa; Lucie Tosca; Gérard Tachdjian; Bruno Leheup; Najet Debili; Isabelle Plo; Jason A Mills; Deborah L French; Mitchell J Weiss; Eric Solary; Remi Favier; William Vainchenker; Hana Raslova
Journal:  Blood       Date:  2014-12-09       Impact factor: 22.113

7.  Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.

Authors:  Chi Keung Cheng; Natalie P H Chan; Thomas S K Wan; Lai Ying Lam; Coty H Y Cheung; Terry H Y Wong; Rosalina K L Ip; Raymond S M Wong; Margaret H L Ng
Journal:  Haematologica       Date:  2016-01-22       Impact factor: 9.941

8.  Runt-related transcription factor 1 contributes to lung cancer development by binding to tartrate-resistant acid phosphatase 5.

Authors:  Changjun He; Xue Bai; Yingbin Li; Haobo Sun; Xianglong Kong; Bicheng Fu; Lantao Chen; Kaibin Zhu; Pengju Li; Shidong Xu
Journal:  Cell Cycle       Date:  2019-10-25       Impact factor: 4.534

Review 9.  RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response.

Authors:  Toshinori Ozaki; Akira Nakagawara; Hiroki Nagase
Journal:  Int J Genomics       Date:  2013-09-03       Impact factor: 2.326

10.  Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.

Authors:  T Ozaki; D Wu; H Sugimoto; H Nagase; A Nakagawara
Journal:  Cell Death Dis       Date:  2013-04-25       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.